"Domestic Top Experts' Regular Work Writes a New Chapter in Heavy Ion Development"​

Professor Liu Yuanzhao, Chairman of the Stereotactic Radiotherapy Committee of the National Tumor Minimally Invasive Industry Alliance and Director of the Radiotherapy Department at Beijing Hospital, has commenced regular guidance work at the Lanzhou Heavy Ion Center.

On July 11, Professor Liu Yuanzhao, Chairman of the Stereotactic Radiotherapy Committee of the National Tumor Minimally Invasive Industry Alliance and Director of the Radiotherapy Department at Beijing Hospital, arrived at the Lanzhou Heavy Ion Center of Wuwei Cancer Hospital to begin a regular working arrangement. This marks the injection of new, strong momentum into the development of the Lanzhou Heavy Ion Center in the field of cancer treatment.

As a senior expert, chief physician, and master's supervisor in radiotherapy, Professor Liu Yuanzhao currently holds multiple key positions: Chairman of the Stereotactic Radiotherapy Committee of the National Tumor Minimally Invasive Industry Alliance; Standing Committee Member of the Nasopharyngeal Cancer Prevention and Treatment Branch of the China International Exchange and Promotive Association for Medical and Health Care; Standing Committee Member of the Pediatric Oncology Committee of the Chinese Research Hospital Association; Vice Chairman of the Head and Neck Cancer Molecular Diagnosis and Treatment Committee of the Beijing Anti-Cancer Association; Member of the Radiation Oncology Society of the Beijing Medical Association; Deputy Leader of the Adenoid Cystic Carcinoma Group of the Tumor Multidisciplinary Committee of the Beijing Medical Award Foundation; Editorial Board Member of the Chinese Journal of Metastatic Tumors and the Chinese Journal of Minimally Invasive Surgery; Beijing Bid Evaluation Expert; and Beijing Medical Record Quality Review Expert. He is engaged in cancer radiotherapy and related research, possessing extensive clinical experience, particularly in the diagnosis and treatment of head and neck tumors. He has treated nearly a thousand head and neck cancer patients using X-ray stereotactic therapy. In recent years, he has focused on high-dose irradiation for early-stage tumors and guided intensity-modulated radiation therapy, enabling curative treatment for elderly cancer patients.

Professor Liu Yuanzhao's regular work at the center represents a significant achievement for the Lanzhou Heavy Ion Center of Wuwei Cancer Hospital in promoting the Heavy Ion Therapy Alliance and establishing 50 expert workstations. This aligns with the hospital's long-standing talent development strategy. Over the years, the hospital has consistently engaged renowned experts including Professor Tatsuaki Kanai from Gunma University, Japan; former Director Professor Hirohiko Tsujii from the National Institute of Radiological Sciences (NIRS); former Director Professor Jörg Hauffe and Professor Olga from the RPTC Proton Therapy Center in Munich, Germany; former Chairman Professor Yi-Min Jen and renowned radiotherapy physicist Professor Chia-Ming Wu from Chang Gung Memorial Hospital, Taiwan; and the team led by Professor Junjie Wang, Chairman of the Radiotherapy Oncology Committee of the Chinese Medical Association. Recently, the hospital has further introduced Professor Yasuo Yoshioka from the Cancer Institute Hospital of JFCR, Japan; Professor Kohei Takizawa, Japan; Professor Shiro Saito, Japan; Professor György Kovács, Director of the Brachytherapy Center Lübeck, Germany and Director of Educational Programs at Università Cattolica del Sacro Cuore, Italy; and Professor Tung-Ho Wu from the TMU Proton Therapy Center at Taipei Medical University Hospital for long-term collaboration. The addition of these top-tier experts has established an expert think tank covering the entire heavy ion therapy chain and integrating Eastern and Western expertise, significantly strengthening the talent matrix.

During ward rounds, Professor Liu Yuanzhao visited patient rooms to meticulously understand each patient's condition and treatment progress, engaging in in-depth discussions with doctors from various radiotherapy departments. Based on individual patient circumstances, he provided precise and personalized treatment recommendations. He particularly emphasized that cancer treatment is a comprehensive and complex process, requiring holistic consideration of numerous factors including the patient's physical condition, tumor type, and stage to tailor the most suitable treatment plan for each patient.

We firmly believe that under the outstanding leadership of Professor Liu Yuanzhao and other eminent figures in the field, the Lanzhou Heavy Ion Center will harness innovation as a powerful driving force. It will accelerate with full commitment toward becoming an internationally top-tier heavy-ion oncology treatment center that integrates clinical care, scientific research, and talent cultivation. This will reshape the landscape of cancer treatment, rekindling hope for global cancer patients. Driven by this momentum, China's oncology sector will steadily ascend toward international leadership, promising a bright future.